Humana thrilled CMS-and shocked its competitors-by offering stand-alone drug insurance plans under Medicare for less than $10 per month. Pharmaceutical manufacturers should applaud. Not all Part D strategies are equal for pharma companies. Manufacturers should compare Humana's approach to other aggressive bids by UnitedHealth and WellCare.
By Michael McCaughan
There are plenty of big numbers associated with the Medicare prescription drug benefit:
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.
Japan's NHI program continues to give and take as 11 new drugs are granted reimbursement, while the prices of others - including three ophthalmic therapies - are cut by up to 20% under a Market Expansion Repricing scheme.
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.
